Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk
McCoy R, Swarna K, Neumiller J, Polley E, Deng Y, Mickelson M, Herrin J. Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Clinical Diabetes 2024 DOI: 10.2337/cd24-0007.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2Moderate cardiovascular disease riskRisk of severe hypoglycemiaGlucose-lowering therapyCardiovascular disease riskType 2 diabetesSevere hypoglycemiaSodium-glucose cotransporter 2 inhibitorsDPP-4GLP-1 receptor agonistsGlucagon-like peptide 1Risk of hypoglycemiaDPP-4 inhibitorsDipeptidyl peptidase 4Disease riskAvoidance of hypoglycemiaSulfonylurea therapyReceptor agonistsCotransporter 2Sulfonylurea usePatient populationGLP-1Peptidase 4HypoglycemiaEmergency departmentComparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy
Barkmeier A, Herrin J, Swarna K, Deng Y, Polley E, Umpierrez G, Galindo R, Ross J, Mickelson M, McCoy R. Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy. Ophthalmology Retina 2024, 8: 943-952. PMID: 38735641, DOI: 10.1016/j.oret.2024.05.003.Peer-Reviewed Original Research